BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-859 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-859\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07736638-11135@assetmemo.bio
DTSTAMP:20261121T005429Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:ABBV-859: Phase 1 readout est. (NCT07736638)
DESCRIPTION:ABBV-859\, phase 1.\nStudy: A Study to Assess the Safety\, Tole
 rability and How Single Ascending Doses of ABBV-859 Moves Through the Body
  of Healthy Adult Participants\nEstimated primary completion: February 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/abbv-859#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07736638
URL:https://assetmemo.bio/drug/abbv-859#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
